Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials

J Clin Oncol. 2014 Jul 1;32(19):2115-6. doi: 10.1200/JCO.2014.55.8866. Epub 2014 May 27.

Authors

James M Mountz¹, Thomas E Yankeelov², Daniel L Rubin³, John M Buatti⁴, Bradley J Erikson⁵, Fiona M Fennessy⁶, Robert J Gillies⁷, Wie Huang⁸, Michael A Jacobs⁹, Paul E Kinahan¹⁰, Charles M Laymon¹¹, Hannah M Linden¹⁰, David A Mankoff¹², Lawrence H Schwartz¹³, Hyunsuk Shim¹⁴, Richard L Wahl⁹

Affiliations

¹ University of Pittsburgh, Pittsburgh, PA mountzjm@upmc.edu.
² Vanderbilt University, Nashville, TN.
³ Stanford University, Palo Alto, CA.
⁴ University of Iowa, Iowa City, IA.
⁵ Mayo Clinic, Rochester, MN.
⁶ Brigham and Women's Hospital, Boston, MA.
⁷ H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
⁸ Oregon Health and Science University, Portland, OR.
⁹ Johns Hopkins University, Baltimore, MD.
¹⁰ University of Washington, Seattle, WA.
¹¹ University of Pittsburgh, Pittsburgh, PA.
¹² University of Pennsylvania, Philadelphia, PA.
¹³ Columbia University, New York, NY.
¹⁴ Emory University, Atlanta, GA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Diagnostic Imaging / methods*
Disease Progression
Humans
Inflammation / chemically induced
Inflammation / etiology*
National Cancer Institute (U.S.)
Neoplasms / diagnosis*
Neoplasms / drug therapy
Neoplasms / radiotherapy
Neoplasms / therapy*
Predictive Value of Tests
Research Support as Topic
Treatment Outcome
United States

Substances

Antineoplastic Agents

Grants and funding